Roche pays $184M to snag mtm diagnostics ops

Demonstrating once again that it's willing to invest in diagnostics, Roche has inked a deal to buy mtm laboratories for €130 million down with another €60 million promised in milestones. The German company develops in vitro diagnostics, specializing in the detection and diagnosis of cervical cancer. Roche has been spending heavily on diagnostics, putting its money where its mouth is in pursuit of more personalized therapies. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.